John Reed, Sanofi R&D chief (Jeff Rumans)

Sanofi flash­es more PhI­II da­ta on new mul­ti­ple myelo­ma drug, set­ting up bat­tle with Darza­lex

Two months af­ter nab­bing their first ap­proved can­cer drug in a decade, Sanofi an­nounced new late-stage da­ta bur­nish­ing the drug’s ef­fi­ca­cy in an­oth­er com­bi­na­tion for mul­ti­ple myelo­ma.

In a 302-per­son Phase III tri­al, in­ves­ti­ga­tors com­bined the new drug, known as Sar­clisa, with Am­gen’s Kypro­lis and showed that the cock­tail was more ef­fec­tive than Kypro­lis alone. Al­though Sanofi did not re­lease da­ta, they said the in­de­pen­dent re­view board had stopped it af­ter the com­bo showed “sig­nif­i­cant­ly pro­longed pro­gres­sion-free sur­vival.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.